Positive Final 2-Year Topline Data in Completed DC Vaccine Phase I/II trial in AML Patients

by NASDAQ Market News January 10, 2020

NASDAQ Market News
Click here to email author

Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annual Meeting

The Next Generation of Innovative Immunotherapy Agents, Inflammasome Inhibitors, Will Be Addressed in Panel Discussion on Monday, Feb. 17, 2020, at 10 a.m. EST

Ads